Praxis Precision Medicines Inc. (PRAX) News

Praxis Precision Medicines Inc. (PRAX): $44.08

1.37 (+3.21%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add PRAX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#285 of 360

in industry

Filter PRAX News Items

PRAX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest PRAX News From Around the Web

Below are the latest news stories about PRAXIS PRECISION MEDICINES INC that investors may wish to consider to help them evaluate PRAX as an investment opportunity.

Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade

The mean of analysts' price targets for Praxis Precision Medicines, Inc. (PRAX) points to a 495% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 30, 2023

Praxis Precision Medicines to Showcase Largest Pipeline of Precision Epilepsy Programs and Breadth of Commitment to Epilepsy Treatments at Upcoming Meetings

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations on its epilepsy programs at the following upcoming meetings in Orlando, Florida. Presentations at the American Epilepsy Society (AES) Annual Meeting,

Yahoo | November 28, 2023

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | November 24, 2023

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside discussion at the Piper Sandler Healthcare Conference on November 28, 2023 at 10:00am. The event will be available via live webcast throug

Yahoo | November 21, 2023

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

BOSTON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that the European Medical Agency (EMA) has awarded its Priority Medicines (PRIME) designation for elsunersen (PRAX-222) for the treatment of SCN2A Gain of Function (GoF) developmental a

Yahoo | November 16, 2023

Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 14, 2023

Praxis Precision Medicines Inc (PRAX) Reports Q3 2023 Financial Results

Company's Cash Position Supports Runway into Q1 2025, R&D Expenses Decrease by 43.5% Year-Over-Year

Yahoo | November 7, 2023

Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development Cash of $101.1 million as of September 30, 2023 supports runway into Q1 2025 BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CN

Yahoo | November 7, 2023

Praxis Precision Medicines to Present at Truist Securities BioPharma Symposium

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a panel discussion titled “CNS Companies Looking To Address High Unmet High Prevalence and High Value Diseases” at the Truist Securities BioPharma Sy

Yahoo | November 2, 2023

Praxis Precision Medicines Stock Down 11% But Insiders Still In US$62k Profit

Praxis Precision Medicines, Inc. ( NASDAQ:PRAX ) insiders who acquired shares over the previous 12 months, can probably...

Yahoo | October 14, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!